Palliative therapy as a single agent or in established combination therapy w/ other approved chemotherapeutic agents in: Brain tumors- glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, metastatic brain tumors; multiple myeloma in combination w/ prednisone; Hodgkin's disease as secondary therapy in combination w/ other approved drugs in patients who relapse while being treated w/ primary therapy, or who fail to respond to primary therapy; non-Hodgkin's lymphomas as secondary therapy in combination w/ other approved drugs for patients who relapse while being treated w/ primary therapy, or who fail to respond to primary therapy.
As a single agent in previously untreated patients: 150-200 mg/m2 IV every 6 wk, given as a single dose or divided into daily inj eg, 75-100 mg/m2 on 2 successive days.
Pulmonary toxicity. Bone marrow toxicity. Development of secondary malignancies w/ long-term use. Inj site reactions. Carcinogenic potential. Should not be given more frequently than every 6 wk. Monitor blood counts wkly for at least 6 wk after a dose. Periodically monitor liver & renal function tests. Perform baseline pulmonary function studies w/ frequent pulmonary function tests during treatment. Accidental contact of reconstituted BiCNU w/ the skin has caused transient hyperpigmentation of the affected area. May cause fetal harm when administered to pregnant woman. Discontinue breastfeeding while on treatment. Ped patients. Elderly.
Sign Out
